Literature DB >> 35217816

The role of REV-ERB in NASH.

Kristine Griffett1, Matthew E Hayes2, Michael P Boeckman1, Thomas P Burris3.   

Abstract

REV-ERBs are atypical nuclear receptors as they function as ligand-regulated transcriptional repressors. The natural ligand for the REV-ERBs (REV-ERBα and REV-ERBβ) is heme, and heme-binding results in recruitment of transcriptional corepressor proteins such as N-CoR that mediates repression of REV-ERB target genes. These two receptors regulate a large range of physiological processes including several important in the pathophysiology of non-alcoholic steatohepatitis (NASH). These include carbohydrate and lipid metabolism as well as inflammatory pathways. A number of synthetic REV-ERB agonists have been developed as chemical tools and they show efficacy in animal models of NASH. Here, we will review the functions of REV-ERB with regard to their relevance to NASH as well as the potential to target REV-ERB for treatment of this disease.
© 2022. The Author(s), under exclusive licence to Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Chinese Pharmacological Society.

Entities:  

Keywords:  Heme; NASH; REV-ERB; circadian clock; inflammation; lipid and glucose metabolism

Mesh:

Substances:

Year:  2022        PMID: 35217816      PMCID: PMC9061770          DOI: 10.1038/s41401-022-00883-w

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   7.169


  109 in total

Review 1.  Rev-erb alpha gives a time cue to metabolism.

Authors:  Hélène Duez; Bart Staels
Journal:  FEBS Lett       Date:  2007-08-24       Impact factor: 4.124

Review 2.  The nuclear receptors Rev-erbs and RORs integrate circadian rhythms and metabolism.

Authors:  Hélène Duez; Bart Staels
Journal:  Diab Vasc Dis Res       Date:  2008-06       Impact factor: 3.291

3.  Activation of Rev-erbα attenuates lipopolysaccharide-induced inflammatory reactions in human endometrial stroma cells via suppressing TLR4-regulated NF-κB activation.

Authors:  Weijie Zhao; Liyuan Cui; Xixi Huang; Songcun Wang; Dajin Li; Liping Li; Yan Sun; Meirong Du
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2019-09-06       Impact factor: 3.848

Review 4.  Current and emerging therapies in nonalcoholic fatty liver disease.

Authors:  Maryam R Kashi; Dawn M Torres; Stephen A Harrison
Journal:  Semin Liver Dis       Date:  2008-10-27       Impact factor: 6.115

Review 5.  Mechanisms of NAFLD development and therapeutic strategies.

Authors:  Scott L Friedman; Brent A Neuschwander-Tetri; Mary Rinella; Arun J Sanyal
Journal:  Nat Med       Date:  2018-07-02       Impact factor: 53.440

6.  Rev-erb regulation of cholesterologenesis.

Authors:  Sadichha Sitaula; Jinsong Zhang; Fernanda Ruiz; Thomas P Burris
Journal:  Biochem Pharmacol       Date:  2017-02-15       Impact factor: 6.100

Review 7.  The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity.

Authors:  Mikhaïl A Van Herck; Jonas Weyler; Wilhelmus J Kwanten; Eveline L Dirinck; Benedicte Y De Winter; Sven M Francque; Luisa Vonghia
Journal:  Front Immunol       Date:  2019-02-06       Impact factor: 7.561

8.  The nuclear receptor REV-ERBα modulates Th17 cell-mediated autoimmune disease.

Authors:  Christina Chang; Chin-San Loo; Xuan Zhao; Laura A Solt; Yuqiong Liang; Sagar P Bapat; Han Cho; Theodore M Kamenecka; Mathias Leblanc; Annette R Atkins; Ruth T Yu; Michael Downes; Thomas P Burris; Ronald M Evans; Ye Zheng
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-27       Impact factor: 11.205

9.  REV-ERBα and REV-ERBβ function as key factors regulating Mammalian Circadian Output.

Authors:  Ryosuke Ikeda; Yoshiki Tsuchiya; Nobuya Koike; Yasuhiro Umemura; Hitoshi Inokawa; Ryutaro Ono; Maho Inoue; Yuh Sasawaki; Tess Grieten; Naoki Okubo; Kazuya Ikoma; Hiroyoshi Fujiwara; Toshikazu Kubo; Kazuhiro Yagita
Journal:  Sci Rep       Date:  2019-07-15       Impact factor: 4.379

10.  REV-ERBα Regulates TH17 Cell Development and Autoimmunity.

Authors:  Mohammed Amir; Sweena Chaudhari; Ran Wang; Sean Campbell; Sarah A Mosure; Laura B Chopp; Qun Lu; Jinsai Shang; Oliver B Pelletier; Yuanjun He; Christelle Doebelin; Michael D Cameron; Douglas J Kojetin; Theodore M Kamenecka; Laura A Solt
Journal:  Cell Rep       Date:  2018-12-26       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.